The University of Missouri/Ellis Fischel Cancer Center (UMC/EFCC) has been an active participant in the activities of Cancer and Leukemia Group B(CALGB) since 1969. During this period, over 2,100 patients have been entered on CALGB clinical trials. Our goals during the next funding period are to continue our participation by enrollment of patients on the CALGB protocols to participate in the development of new protocols and the analysis of those completed. The institutions involved include the UMC/EFCC and the adjacent Harry S. Truman Veteran's Memorial Hospital, which share a common faculty . We will also enter patients from the private practice of Hematology-Oncology Associates at Boone Hospital Center and Columbia Regional Hospital (both in Columbia, Missouri), the Missouri Baptist Cancer Center and St. Luke's Hospital (both in St. Louis, Missouri) and the University of Missouri-Kansas City. Members of the UMC/EFCC and its affiliates contribute to the group's scientific committees, serve as study chairs, contribute patients, attend CALGB meetings, and serve on administrative committees. As an institution, we are one of the largest contributors to CALGB respiratory cancer and a significant contributor to breast cancer studies. We accrue approximately one acute leukemia patient per month and enter a small number of untreated lymphoma patients and patients with colon cancer. Two new affiliates have been added to increase accrual in all of these areas. The methodology involves the production of a protocol or treatment plan. The initial idea may come from an individual or derive from a meeting of one of the CALGB disease committees (breast, gastrointestinal , lung, leukemia, and lymphoma) or a modality committee (pharmacology and experimental therapeutics, radiotherapy, surgery, and psycho-oncology). The protocol is modified, if necessary, and approved by the participating Modality Committees and then by the Executive Committee of CALGB. The final protocol is then submitted to the National Cancer Institute for approval. The protocol is activated at each of the participating institutions (following approval by their respective Institutional Review Boards). Patients are then enrolled until accrual goals are met, at which time the protocol is closed. The results are tabulated, statistically analyzed, and subsequently published. Sequential studies build upon the results of completed clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA012046-21
Application #
3556067
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1998-03-31
Budget Start
1993-05-10
Budget End
1994-03-31
Support Year
21
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Missouri-Columbia
Department
Type
Schools of Medicine
DUNS #
112205955
City
Columbia
State
MO
Country
United States
Zip Code
65211
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Jaklitsch, Michael T; Gu, Lin; Demmy, Todd et al. (2013) Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. J Thorac Cardiovasc Surg 146:9-16
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Edelman, Martin J; Hodgson, Lydia; Rosenblatt, Paula Y et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7:649-54

Showing the most recent 10 out of 100 publications